Compare ATRC & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRC | ARDX |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2005 | 2014 |
| Metric | ATRC | ARDX |
|---|---|---|
| Price | $28.80 | $7.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $51.17 | $15.14 |
| AVG Volume (30 Days) | 706.1K | ★ 3.5M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.74 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $201,630,000.00 | $2,607,000.00 |
| Revenue This Year | $15.27 | $37.75 |
| Revenue Next Year | $12.21 | $34.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.40 | N/A |
| 52 Week Low | $26.62 | $3.50 |
| 52 Week High | $43.18 | $8.40 |
| Indicator | ATRC | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 75.50 |
| Support Level | $28.03 | $6.83 |
| Resistance Level | $30.75 | $8.05 |
| Average True Range (ATR) | 1.36 | 0.33 |
| MACD | 0.12 | 0.11 |
| Stochastic Oscillator | 54.98 | 95.03 |
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.